Intravesical treatment of overactive bladder

Area of Science:

• Urology
• Pharmacology
• Neuroscience

Background:

• Intravesical agents are primarily used for neurogenic bladder disorders with severe detrusor hyperreflexia (DH) and incomplete emptying.
• Patients often perform intermittent self-catheterization due to residual urine, making intravesical medication suitable.
• Current strategies focus on reducing parasympathetic efferent activity or de-afferenting the bladder.

Purpose of the Study:

• To review the use and potential of intravesical agents for treating detrusor hyperreflexia (DH).
• To explore mechanisms of action, including cholinergic blockade and afferent nerve modulation.
• To evaluate specific agents like oxybutynin, atropine, local anesthetics, capsaicin, and resiniferatoxin (RTX).

Main Methods:

• Review of existing literature on intravesical treatments for overactive bladder and detrusor hyperreflexia (DH).
• Discussion of pharmacological mechanisms, including cholinergic transmission blockade and afferent pathway targeting.
• Comparison of different intravesical agents based on efficacy, duration, and side effect profiles.

Main Results:

• Intravesical oxybutynin shows effectiveness in resistant DH, potentially via local anesthetic and cholinergic blockade.
• Intravesical atropine may increase bladder capacity, but clinical utility for DH requires further study.
• Capsaicin and its analog RTX target capsaicin-sensitive bladder afferents, with RTX offering a non-irritant profile.

Conclusions:

• Intravesical agents provide an alternative to oral medications for overactive bladder and DH.
• These agents offer the potential for targeted therapy by selectively affecting implicated end organs.
• Further research is needed to fully establish the clinical role of agents like atropine, capsaicin, and RTX.